Riley Kandel

Articles

FDA Awards National Priority Voucher to Teclistamab Plus Daratumumab in R/R Myeloma

December 15th 2025

The FDA has given a national priority voucher to teclistamab plus daratumumab for relapsed/refractory multiple myeloma, based on MajesTEC-3 data.

Gedatolisib Plus Fulvestrant ± Palbociclib Is a Potential New SOC in HR+ PIK3CA Wild-Type Advanced Breast Cancer

December 12th 2025

Gedatolisib regimens showed PFS benefits irrespective of prior treatment duration in HR-positive, HER2-negative PIK3CA wild-type advanced breast cancer.

Long-Term PALLAS Data Show No Adjusted OS Difference With Adjuvant Palbociclib in HR+/HER2– Breast Cancer

December 12th 2025

An adjusted OS analysis showed no OS difference with the addition of adjuvant palbociclib in HR-positive/HER2-negative breast cancer.

Real-World Data Showcase Efficacy of Adjuvant Pembrolizumab in ccRCC

December 11th 2025

Pembrolizumab in the adjuvant setting yielded high DFS and OS results in addition to a manageable safety profile in real-world patients with ccRCC.

Belzutifan Maintains Efficacy After a PD-(L)1 Inhibitor and Multiple VEGFR TKIs in ccRCC

December 11th 2025

Belzutifan maintained efficacy benefits vs everolimus among patients with ccRCC after at least 2 prior VEGFR TKIs.

Orca-Q Yields Low Rates of GVHD and Non-Relapse Mortality in High-Risk Hematologic Malignancies

December 10th 2025

Myeloablative Orca-Q demonstrated efficacy and safety in high-risk hematologic malignancies.

Limited-Duration Teclistamab Drives Durable Responses in Relapsed/Refractory Myeloma

December 9th 2025

Early teclistamab discontinuation after deep response showed PFS comparable to continuous therapy in relapsed/refractory myeloma in the LimiTEC trial.

Dr Freedland on the Next Steps for Evaluating Enzalutamide in Prostate Cancer

December 8th 2025

Stephen J. Freedland, MD, discusses future avenues for research with enzalutamide in biochemically recurrent prostate cancer.

INCA033989 With/Without Ruxolitinib Is Safe, Drives Spleen and Anemia Responses in CALR Exon 9–Mutated Myelofibrosis

December 7th 2025

INCA033989 given with or without ruxolitinib was well tolerated and yielded spleen and anemia responses in myelofibrosis with CALR exon 9 mutations

Revumenib Plus Decitabine/Cedazuridine and Venetoclax Proves Efficacious in Newly Diagnosed AML

December 7th 2025

The SAVE regimen shows high response and MRD negativity rates in patients with AML, but myelosuppression and infectious complications remain key concerns.

Elranatamab Plus Iberdomide Shows Early Efficacy in R/R Multiple Myeloma

December 6th 2025

Elranatamab plus iberdomide showed a 95.5% response rate in patients with BCMA-naive relapsed/refractory myeloma per early MagnetisMM-30 data.

Addition of Daratumumab to Lenalidomide Maintenance May Improve MRD-Negative Conversion Rates in Newly Diagnosed Myeloma

December 4th 2025

Larry Anderson, MD, PhD, FACP, discusses data from AURIGA showing that daratumumab plus lenalidomide is a favorable maintenance regimen in multiple myeloma.

TUB-040 Represents Novel ADC Approach in Platinum-Resistant Ovarian Cancer

December 3rd 2025

Antonio González-Martín, MD, PhD, discusses data for TUB-040 in platinum-resistant ovarian cancer and how it stacks up against other ADCs.

Copanlisib/Ibrutinib Data Highlight Potential for PI3K Inhibition in R/R PCNSL

December 2nd 2025

BTK and PI3K inhibition produced responses but unexpected PK data in relapsed/refractory PCNSL.

NICE Recommends Obe-Cel for Adult R/R B-ALL

December 1st 2025

NICE has recommended obecabtegene autoleucel for adult patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

Dr Freedland on the Increasingly Prominent Role of Enzalutamide in Prostate Cancer Treatment

December 1st 2025

Stephen Freedland, MD, discusses how findings from the phase 3 EMBARK trial suggest a new standard of care in prostate cancer.

FDA Approval of Daratumumab Opens Treatment Options for High-Risk Smoldering Myeloma

December 1st 2025

Peter Voorhees, MD, discusses the FDA approval of daratumumab for patients with high-risk smoldering multiple myeloma.

Durvalumab Plus Concurrent Chemoradiotherapy Fails to Show PFS or OS Benefit in NSCLC

November 28th 2025

Durvalumab administered with chemoradiotherapy rather than afterwards generated no significant improvement in PFS, OS, or ORR for patients with NSCLC.

Evolving Approaches With BTK Inhibition and Targeted Therapy Seek to Improve Outcomes in High-Risk MCL

November 26th 2025

Christine Ryan, MD, discusses the limitations of current MCL treatment strategies, advances in treatment, and the evolving role of BTK inhibition.

Intraventricular B7-H3–Targeted CAR T-Cell Therapy Displays Safety in Recurrent Glioblastoma

November 25th 2025

B7-H3–directed CAR T cell therapy was well-tolerated and demonstrated an acceptable safety profile in recurrent glioblastoma.